About IN8bio, Inc.
https://in8bio.comIN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers.
CEO
Tai-Wei Ho
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-06 | Reverse | 1:30 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BIOS CAPITAL MANAGEMENT, LP
Shares:286.66K
Value:$633.53K
BLACKROCK INC.
Shares:57.08K
Value:$126.15K
Summary
Showing Top 2 of 2
About IN8bio, Inc.
https://in8bio.comIN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $3.85M ▼ | $-3.85M ▲ | 0% | $-0.85 ▲ | $-3.33M ▲ |
| Q2-2025 | $0 | $5.09M ▼ | $-5.09M ▲ | 0% | $-1.24 ▼ | $-4.42M ▲ |
| Q1-2025 | $0 | $5.55M ▼ | $-5.55M ▲ | 0% | $-0.07 ▲ | $-4.99M ▲ |
| Q4-2024 | $0 | $6.16M ▼ | $-6.16M ▲ | 0% | $-0.09 ▲ | $-5.52M ▼ |
| Q3-2024 | $0 | $7.09M | $-7.09M | 0% | $-0.15 | $-5.35M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $10.69M ▼ | $16.77M ▼ | $3.58M ▼ | $13.19M ▼ |
| Q2-2025 | $13.23M ▲ | $19.37M ▼ | $4.13M ▼ | $15.24M ▲ |
| Q1-2025 | $11.89M ▲ | $19.87M ▼ | $5.99M ▼ | $13.88M ▼ |
| Q4-2024 | $11.12M ▲ | $20.94M ▲ | $6.47M ▼ | $14.48M ▲ |
| Q3-2024 | $4M | $15.97M | $7.38M | $8.59M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.85M ▲ | $-3.52M ▲ | $0 | $989K ▼ | $-2.54M ▼ | $-3.52M ▲ |
| Q2-2025 | $-5.09M ▲ | $-3.93M ▼ | $0 | $5.27M ▲ | $1.34M ▲ | $-3.93M ▼ |
| Q1-2025 | $-5.55M ▲ | $-3.12M ▲ | $0 ▲ | $3.89M ▼ | $771K ▼ | $-3.12M ▲ |
| Q4-2024 | $-6.16M ▲ | $-4.03M ▲ | $-33K ▼ | $11.19M ▲ | $7.12M ▲ | $-4.06M ▲ |
| Q3-2024 | $-7.09M | $-6.11M | $0 | $-105K | $-6.22M | $-6.11M |
CEO
Tai-Wei Ho
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-06 | Reverse | 1:30 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BIOS CAPITAL MANAGEMENT, LP
Shares:286.66K
Value:$633.53K
BLACKROCK INC.
Shares:57.08K
Value:$126.15K
Summary
Showing Top 2 of 2